CAS 2040295-03-0

PLX3397 HCl

Description:

PLX3397 HCl, also known as pexidartinib, is a small molecule inhibitor primarily targeting the receptor tyrosine kinases, including CSF1R, FLT3, and KIT. It is classified as a kinase inhibitor and is utilized in the treatment of certain cancers, particularly those associated with macrophage infiltration. The hydrochloride salt form enhances its solubility and stability, making it suitable for pharmaceutical applications. PLX3397 HCl exhibits a specific mechanism of action by inhibiting the signaling pathways that promote tumor growth and survival, thereby potentially reducing tumor size and improving patient outcomes. The compound is typically administered orally and has undergone various clinical trials to assess its efficacy and safety profile. Its pharmacokinetics, including absorption, distribution, metabolism, and excretion, are crucial for determining appropriate dosing regimens. As with many targeted therapies, monitoring for adverse effects and drug interactions is essential during treatment. Overall, PLX3397 HCl represents a significant advancement in targeted cancer therapy, particularly for tumors driven by the pathways it inhibits.

Formula: C₂₀H₁₆Cl₂F₃N₅

Synonyms:

• Pexidartinib hcl
• PLX3397 HCl
• Pexidartinib hydrochloride (PLX-3397)
• Pexidartinib Hydrochloride Salt

5-((5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)pyridin-2-amine hydrochloride

CAS: 2040295-03-0

5-((5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)pyridin-2-amine hydrochloride

Purity: 99%

Molecular weight: 454.28g/mol

Ref: 54-PC1006273

Pexidartinib hydrochloride

CAS: 2040295-03-0

Pexidartinib HCl is a potent, selective CSF1R and c-Kit inhibitor with IC50s of 20 nM and 10 nM, respectively, showing anti-tumor activity.

Formula: C₂₀H₁₆Cl₂F₃N₅

Color and Shape: Solid

Molecular weight: 454.28

Ref: TM-T62788

Pexidartinib Hydrochloride Salt

Controlled Product

CAS: 2040295-03-0

Applications Pexidartinib Hydrochloride is RTK inhibitor. It can be used in pharmacological activity, therapeutic use, and biological study of inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
References Mok, S., et al.: BMC Cancer, 15, 1, 2015

Formula: C₂₀H₁₅ClF₃N₅·ClH

Color and Shape: Neat

Molecular weight: 454.276

Ref: TR-P293640

Pexidartinib hydrochloride

CAS: 2040295-03-0

Pexidartinib hydrochloride is a potent, selective inhibitor of the receptor tyrosine kinases (RTKs) insulin-like growth factor 1 receptor (IGF1R) and c-Kit. It has been shown to inhibit the growth of cancer cells and myeloid leukemia cells. Pexidartinib hydrochloride has an excellent safety profile, with no serious adverse effects observed in clinical studies, and it is not associated with the development of drug resistance. The drug was well tolerated in patients with advanced solid tumors or myeloid malignancies who had failed prior treatment with other anticancer agents.

Formula: C₂₀H₁₆Cl₂F₃N₅

Purity: Min. 95%

Molecular weight: 454.3 g/mol

Ref: 3D-QGD29503